Avant Diagnostics, Inc. (OTC: AVDX) is on a mission to
maximize its levels of corporate transparency for the benefit of its customers
and investors. Late last week, the company took a significant step toward
realizing this goal when it unveiled its new website. The new site utilizes a
number of design features aimed at making browsing both streamlined and
informative for Avant’s current and potential customers and investors.
The site’s investor relations section, in particular,
received a considerable upgrade, incorporating helpful features such as
immediate posting of press releases and automated posting of SEC filings, XBRL
data, Insider Section 16 filings and financial statements. Additionally, the
company has incorporated CEO interviews and media coverage, corporate videos
and an up-to-date frequently asked questions section in order to more
adequately inform visitors about Avant’s latest advances.
“A significant part of Avant’s mission is presenting those
interested in the company with the information they want in the quickest and
most organized way,” Gregg Linn, president and chief executive officer of
Avant, stated in a news release. “We believe our new website advances this goal
by presenting our range of services and activities in an attractive and easy-to-access
format.”
In the months to come, Avant in strategically positioned to
continue the development of its pre-symptomatic ovarian cancer screening test,
OvaDx®. Leveraging more than 10 years of research and development and a strong
intellectual property portfolio, the company is seeking to reduce the costs
associated with ovarian cancer detection while helping medical providers avoid
costly late stage disease treatments.
According to data from the American Cancer Society, ovarian
cancer ranks fifth in cancer deaths among women, accounting for more fatalities
than any other cancer of the female reproduction system. However, early
detection can play a major role in improving the survivability of this
dangerous disease. According to the National Cancer Institute, ovarian cancer
cases discovered in stage I development present patients with a five-year
relative survival rate in excess of 92 percent. Despite the benefits of early
detection, only about 15 percent of ovarian cancer cases are currently diagnosed
at stage one.
Through the development of OvaDx, Avant is seeking to
provide a more effective option for detecting early stage ovarian cancer. The
microarray-based diagnostic test, which, upon FDA approval, is expected to be
offered as an elective test for women with elevated risk of ovarian cancer, has
been shown to detect stage IA disease markers with approximately 80 percent
sensitivity and 100 percent specificity.
For more information, visit www.avantdiagnostics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment